Influence of chemoresistance and p53 status on fluoro-2-deoxy-d-glucose incorporation in cancer

Nuclear Medicine and Biology

Volumn 37, Issue 1, 2010, Pages 51-55

  Smith, Tim A D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Chemoresistance; Fluoro 2 deoxy d glucose; p53; PET

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMATINIB; METHOTREXATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MUTANT PROTEIN; PACLITAXEL; PROTEIN P53; RALTITREXED; TAXANE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CHEMOSENSITIVITY; DRUG BINDING SITE; DRUG INACTIVATION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; GASTROINTESTINAL TUMOR; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, NEOPLASM; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72449143571     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.08.007     Document Type: Article

References (48)

1. Goldie J.H. Drug resistance in cancer: a perspective. Cancer Metastasis Rev 20 (2001) 63-68
2. Loeb L.A. A mutator phenotype in cancer. Cancer Res 61 (2001) 3230-3239
3. Sood A.K., and Buller R.E. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol 92 (1998) 312-319
4. Borst P., and Pinedo H.M. Drug resistance. In: Peckham M., Pinedo H.M., and Veronesi U. (Eds). Oxford Textbook of Oncology (1995), Oxford University, New York 586-601
5. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
6. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. - fundamental and molecular mechanisms of mutagenesis. Mutat Res 478 (2001) 23-43
7. Sampath D., Greenberger L.M., Beyer C., Hari M., Liu H., Baxter M., et al. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clin Cancer Res 12 (2006) 3459-3469
8. Shalli K., Brown I., Heys S.D., and Schofield A.C. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19 (2005) 1299-1301
9. Pfeifer G.P., and Besaratinia A. Mutational spectra of human cancer. Hum Genet 125 (2009) 493-506
10. Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331 (2005) 868-880
11. Aas T., Borresen A.L., Geisler S., SmithSorensen B., Johnsen H., Varhaug J.E., et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2 (1996) 811-814
12. Stilgenbauer S., Bullinger L., Lichter P., Dohner H., and German CLL Study Group (GCLLSG). Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 16 (2002) 993-1007
13. Stokke T., Galteland E., Holte H., Smedshammer L., Suo Z., Smeland E.B., et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell non-Hodgkin's lymphoma. Int J Cancer 89 (2000) 313-324
14. de Graeff P., Crijns A.P.G., de Jong S., Boezen M., Post W.J., de Vries E.G.E., van der Zee A.G.J., et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101 (2009) 149-159
15. Smith T.A.D. The rate limiting step for tumor FDG incorporation. Nucl Med Biol 28 (2001) 1-4
16. Herrmann K., Krause B.J., Bundschuh R.A., Dechow T., and Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med 39 (2009) 210-232
17. Mohan H.K., and Miles K.A. Cost-effectiveness of Tc-99m-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med 50 (2009) 376-381
18. Higashi K., Ueda Y., Ikeda R., Kodama Y., Guo J., Matsunari I., et al. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl Med Commun 25 (2004) 19-27
19. Seo S., Hatano E., Higashi T., Nakajima A., Nakamoto Y., Tada M., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 143 (2008) 769-777
20. Seo S., Hatano E., Higashi T., Nakajima A., Hara T., Tada M., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 13 (2007) 427-433
21. Lorke D.E., Kruger M., Buchert R., Bohuslavizki K.H., Clausen M., and Schumacher U. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J Nucl Med 42 (2001) 646-654
22. Seo S., Hatano E., Higashi T., Nakajima A., Nakamoto Y., Tada M., et al. P-glycoprotein expression affects F-18-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 34 (2009) 1303-1312
23. Yamada K., Brink I., and Engelhardt R. Factors influencing [F-18]2-fluoro-2-deoxy-d-glucose (F-18 FDG) accumulation in melanoma cells: is FDG a substrate of multidrug resistance (MDR)?. J Dermatol 32 (2005) 335-345
24. Bentley J., Bell S.E., Quinn D.M., Kellett G.L., and Warr J.R. 2-Deoxy-d-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncol Res 8 (1996) 77-84
25. Smith T.A.D., Sharma R.I., Wang W.G., Welch A.E., Schweiger L.F., and Collie-Duguid E.S.R. Decreased [F-18]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro. Nucl Med Biol 34 (2007) 955-960
26. 0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65 (2005) 3162-3170
27. Grimpen F., Yip D., McArthur G., Waring P., Goldstein D., Loughrey M., et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol 6 (2005) 724-727
28. Su H., Bodenstein C., Dumont R.A., Seimbille Y., Dubinett S., and Phelps M.E. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12 (2006) 5659-5667
29. Krasznai Z.T., Peli-Szabo J., Nemeth E., Balkay L., Szabo G., Goda K., et al. Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells. Eur J Pharm Sci 28 (2006) 249-256
30. Gonzalez K.D., Noltner K.A., Buzin C.H., Gu D.Q., Wen-Fong C.Y., Nguyen V.Q., et al. Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27 (2009) 1250-1256
31. Masciari S., Van den Abbeele A.D., Diller L.R., Rastarhuyeva I., Yap J., Schneider K., et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. J Am Med Assoc 299 (2008) 1315-1319
32. Buerkle A., and Weber W.A. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 27 (2008) 545-554
33. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48 (2007) 771-775
34. Gil-Rendo A., Martinez-Regueira F., Zornoza G., Garcia-Velloso M.J., Beorlegui C., and Rodriguez-Spiteri N. Association between [F-18]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 96 (2009) 166-170
35. Crippa F., Seregni E., Agresti R., Chiesa C., Pascali C., Bogni A., et al. Association between [F-18]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25 (1998) 1429-1434
36. Taylor M.D., Smith P.W., Brix W.K., Wick M.R., Theodosakis N., Swenson B.R., et al. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 137 (2009) 43-48
37. Zhang Z.J., Chen J.H., L Meng J.J.D.u., Zhang L., Liu Y., et al. F-18-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chin Med J 120 (2007) 125-131
38. van der Veldt A.A.M., Hooft L., van Diest P.J., Berkhof J., MR Buist M.R., et al. Microvessel density and p53 in detecting cervical cancer by FDG PET in cases of suspected recurrence. Eur J Nucl Med Mol Imaging 33 (2006) 1408-1416
39. Tateishi U., Yamaguchi U., Seki K., Terauchi T., Arai Y., and Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [F-18]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33 (2006) 683-691
40. Folpe A.L., Lyles R.H., Sprouse J.T., Conrad E.U., and Eary J.F. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 6 (2000) 1279-1287
41. Trojan J., Schroeder O., Raedle J., Baum R.P., Herrmann G., Jacobi V., et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 94 (1999) 3314-3319
42. Schroder O., Trojan J., Zeuzem S., and Baum R.P. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 37 (1998) 279-285
43. 18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade. Eur Radiol 17 (2007) 409-417
44. Watanabe K., Nomori H., Ohtsuka T., Naruke T., Ebihara A., Orikasa H., et al. [F-18]fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jap J Clin Oncol 36 (2006) 403-409
45. Buck A., Schirrmeister H., Kuhn T., Shen C.X., Kalker T., Kotzerke J., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29 (2002) 1317-1323
46. Sasaki M., Sugio K., Kuwabara Y., Koga H., Nakagawa M., and Chen T. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. Ann Nucl Med 17 (2003) 189-196
47. Smith T.A.D., Sharma R.I., Thompson A.M., and Paulin F.E.M. Tumor F-18-FDG incorporation is enhanced by attenuation of p53 function in breast cancer cells in vitro. J Nucl Med 47 (2006) 1525-1530
48. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrolova O., et al. p53 regulates mitochondrial respiration. Science 312 (2006) 1650-1653